Morningstar

GSK Says Lung-Cancer Drug Shows Benefits in Global Trial

Provided by Dow Jones

By Adria Calatayud 




  GSK said an early-stage global clinical trial of a drug it licensed from China's Hansoh Pharmaceutical Group showed a majority of lung-cancer patients saw their tumors shrink or disappear. 



  The U.K. drugmaker said Monday that the first global results for the drug, risvutatug rezetecan--or ris-rez--, in extensive-stage small cell lung cancer build on positive data from a China-only late-stage study that its partner Hansoh recently reported. 



  GSK said ris-rez triggered a 61% objective response rate--the proportion of patients whose cancer shrinks or disappears after treatment--in the global trial. 



  The data support an accelerated development for the drug, GSK said. The company is conducting late-stage trials of ris-rez in advanced forms of lung and prostate cancers and plans additional studies in earlier phases of the diseases. 





  Write to Adria Calatayud at adria.calatayud@wsj.com 





  (END) Dow Jones Newswires



  October 19, 2026 01:38 ET (05:38 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
 
Even with significant growth potential, the stock’s lofty valuation is difficult to justify. 
 
 
Sean Dunlop, CFA 
 
 
 
10 Best Blue-Chip Stocks to Buy for the Long Term
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
33 Undervalued Stocks to Buy Before the Market Shifts Again
 
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026. 
 
 
Susan Dziubinski and Tori Brovet 
 
 
 
 

			Sponsor Center